NASDAQ:HTBX - Heat Biologics, Inc.
$1.48
 $0.06
+4.23%
1:35PM EDT
2019-02-15
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  HTBX     avg for
industry  
  avg for
sector  
42 stocks weight:  8. 45   0. 00   0. 00  
42 stocks rank:  3. 95 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  
mean recommendation:  2. 00   1. 91   1. 93  

quick ratio:  3. 09   5. 37   1. 81  
current ratio:  3. 45   5. 69   2. 19  

target price low:  2. 55   88. 97   117. 82  
target price avg:  0. 95   115. 19   141. 96  
target price high:  1. 10   143. 40   163. 16  
1-yr high:  4. 17   124. 30   142. 77  
last close:  1. 42   101. 85   127. 84  
50-day avg:  1. 28   98. 27   122. 46  
200-day avg:  1. 78   99. 72   122. 70  
1-yr low:  0. 98   78. 19   100. 16  
volume:  251. 53 K 2. 38 M 4. 64 M
50-day avg volume:  389. 14 K 3. 31 M 4. 94 M
200-day avg volume:  863. 89 K 3. 23 M 4. 28 M

1-day return:  2. 90 % 0. 22 % 0. 48 %
this week return:  7. 58 % 1. 77 % 2. 01 %
12-wk return:  -0. 70 % 6. 56 % 3. 33 %
52-wk return:  -55. 91 % -2. 23 % 14. 35 %

enterprise value (EV):  9. 11 M 55. 17 B 104. 51 B
market cap:  46. 09 M 49. 01 B 96. 46 B
EBITDA:  -14. 88 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 61   -91. 79   2. 29  
enterprise/revenue (EV/R):  2. 09   29. 84   23. 39  
total revenue:  4. 35 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -13. 93 M 2. 37 B 3. 58 B

shares outstanding:  32. 46 M 607. 99 M 1. 22 B
shares:  19. 29 M 605. 53 M 1. 15 B
shares short:  696. 18 K 11. 62 M 12. 55 M
shares short prior month:  483. 51 K 11. 95 M 13. 44 M
short ratio:  1. 29   4. 82   3. 10  
short % of float:  3. 05 % 6. 19 % 2. 82 %
total cash/share:  0. 90   12. 02   11. 46  
total cash:  20. 96 M 7. 41 B 7. 37 B
free cash flow:  -5. 92 M 95. 99 M 2. 04 B
operating cash flow:  -12. 51 M 164. 74 M 3. 04 B

book value:  1. 06   14. 43   28. 26  
price/book:  1. 34   -1. 57   -2. 97  
gross profits:  -6. 75 M 8. 28 B 18. 09 B
operating margins:  -346. 86 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  -204. 30 % 49. 33 % 54. 53 %

1-yr max volatility:  94. 86 % --- ---
1-yr mean volatility:  0. 17 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 15   3. 03   4. 09  
forward EPS:  -0. 68   4. 33   6. 99  
P/E:  -1. 24   6. 11   26. 91  
forward P/E:  -2. 09   8. 38   10. 48  
PE/G:  -0. 00   0. 37   5. 61  
growth:  290. 80 % 683. 72 % 104. 79 %
earnings high:  -0. 17   1. 27   1. 66  
earnings avg:  -0. 20   1. 01   1. 53  
earnings low:  -0. 22   0. 76   1. 40  
revenue high:  1. 80 M 2. 86 B 11. 19 B
revenue avg:  1. 80 M 2. 78 B 10. 84 B
revenue low:  1. 80 M 2. 67 B 10. 64 B
return on assets:  -40. 08 % -3. 27 % 3. 81 %
return on equity:  -102. 02 % 107. 48 % 27. 82 %
revenue growth:  290. 80 % 648. 36 % 97. 70 %
revenue/share:  0. 36   14. 68   59. 83  

beta (1yr vs S&P500):  0. 91   1. 21   0. 93  
sharpe (1yr):  0. 26   0. 06   0. 98  

held % insiders:  3. 80 % 6. 46 % 3. 21 %
held % institutions:  25. 15 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : HTBX
.    + 0.047 =         0.047 :: INITIAL WEIGHT
.  + 134.504 =       134.551 :: inverse volume-to-price addition
.  + 178.929 =        313.48 :: spline projection addition
.  - 173.354 =       140.126 :: poor performance penalty
.    x 0.689 =        96.522 :: one-year gains+dividend factor
.    x 7.467 =       720.708 :: 13 weeks' performance factor
.    x 1.492 =      1075.649 :: industry recommendation factor
.    x 2.098 =      2256.885 :: symbol recommendation factor
.     x 1.07 =      2415.282 :: EV/R factor
.    x 0.996 =      2405.601 :: return on assets factor
.     x 0.99 =      2381.059 :: return on equity factor
.    x 2.426 =      5776.622 :: revenue growth factor
.    x 2.606 =     15053.573 :: current ratio factor
.    x 1.216 =     18309.665 :: quick ratio factor
.    x 1.332 =     24395.139 :: short ratio factor
.    x 2.013 =     49116.465 :: price-to-book factor
.    x 1.084 =     53227.399 :: 5-day avg > 50-day avg
.    x 2.169 =    115475.992 :: P/E weight
.    x 2.209 =    255081.745 :: PE/G factor
.    x 1.622 =    413842.902 :: beta factor
.    x 0.257 =    106277.997 :: sharpe factor
.    x 1.982 =    210641.634 :: target low factor
.    x 0.898 =    189162.147 :: target mean factor
.    x 0.953 =     180182.38 :: target high factor
.    x 1.066 =    192004.652 :: industry 12-weeks return
.    x 0.965 =    185312.895 :: "drift" penalty 2 days ago
.    x 0.998 =    184963.123 :: overall "drift" factor
.    x 0.051 =      9507.461 :: largest single-day jump factor
.    x 0.063 =       603.265 :: low price factor
.      x 1.0 =       603.306 :: factor hist industry gain for week 06
.   cubeRoot =          8.45 :: reduced for readability
.                       8.45 :: FINAL WEIGHT for NASDAQ:HTBX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org